So, CGRP is really a key player for migraine pathogenesis, but it is still not certain if it also plays a role in cortical spreading depression mechanisms and so in migraine with aura. But really preclinical evidence has shown that CGRP is also released during cortical spreading depression. And also we all know that there is a coupling between cortical spreading depression and the trigeminal system activation and the release of CGRP from the trigeminal endings...
So, CGRP is really a key player for migraine pathogenesis, but it is still not certain if it also plays a role in cortical spreading depression mechanisms and so in migraine with aura. But really preclinical evidence has shown that CGRP is also released during cortical spreading depression. And also we all know that there is a coupling between cortical spreading depression and the trigeminal system activation and the release of CGRP from the trigeminal endings. So I think everything is connected all together. And now we have also indirect evidence that is coming from the clinical practice. In fact, monoclonal antibodies, anti-CGRP have demonstrated that they also work, they’re also effective in the treatment of migraine with aura. So, all together, really points to an importance of CGRP in migraine with aura pathogenesis and also in the mechanisms of cortical spreading depression.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.